Loading... (0%)

News + Events

news

3­‐V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012

01 October 2012

Menlo Park, California, October 1, 2012. 3­‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9‐13 in Boston, Massachusetts. 3‐V Biosciences is discovering and developing oral antiviral therapeutics designed to…

3-V Biosciences Closes Preferred Stock Financing and Designates Novel Host-Factor Hepatitis C Program

09 July 2012

Menlo Park, California, January 5, 2012. 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the designation of a novel program targeting a host-factor for the treatment of Hepatitis C virus (HCV). “The continued support of the company’s investors for the host-factor vision reflects both the success of the team thus…

3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology

29 June 2012

Menlo Park, California, June 29, 2012. 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology.  Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development. “With our…

James F. Young joins 3-V Biosciences Board of Directors

20 July 2010

Menlo Park, California, July 20, 2010. 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors. “We are very pleased to welcome Jim Young to the 3-V Board,” said David M. Mott, 3-V’s Executive Chairman. “Jim’s expertise as a virologist, immunologist, drug developer and company builder make him…

3-V Biosciences Appoints Edward M. Connor, Jr., MD, Chief Medical Officer

03 June 2010

Menlo Park, California, June 3, 2010. 3-V Biosciences, Inc. announced today the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer. “Ed Connor is among the most experienced respiratory infectious disease drug developers in the world, having led the development of RespiGam and Synagis® for respiratory syncytial virus and FluMist® for influenza,” said…

3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations

13 May 2010

Menlo Park, California, May 13, 2010. 3-V Biosciences, Inc. announced today the appointment of Stephen R. Brady to the post of Vice President, Corporate Development, Strategy & Operations, the consolidation of all preclinical research under Robert S. McDowell, Ph.D. as Vice President, Research, and the integration of the company into new office and lab space in Menlo Park,…